AAMI Consensus Report

End User Disclosures for Emergency Use

Ventilatory Assistance Helmet (VAH)

AAMI CR509:2020/(R)2022
End user disclosures for emergency use Ventilatory Assistance Helmet (VAH)

Revisions are expected to be made to this document as the COVID-19 situation evolves. Please go to https://www.aami.org/covid_cr to find the most current version as well as past versions. This document is freely available and may be shared with all interested stakeholders. Contact celliott@aami.org with any comments or questions.

Approved 16 July 2020 and reaffirmed 6 October 2022 by AAMI

Abstract: Identifies safety related disclosures to be provided to end users of Emergency Use VAH. These details are based on the hazards identified in IEC 60601-1 and ISO 17510.

Keywords: COVID-19
AAMI Consensus Report

A Consensus Report (CR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) developed to provide concise, prompt and practical guidance on narrowly focused topics of high importance to the health technology community. A Consensus Report is intended provide initial consensus guidance in response to an urgent/immediate need for guidance in the following instances:

- While more robust data/information develops on emergent areas
- When variation in the development, implementation or use of a product or process exists
- When existing standards or other documents require additional context/clarification

A Consensus Report is not subject to the same formal process as a standard and while similar in nature to a technical information report (TIR), a CR is based on the collective knowledge and experience of a selected group of stakeholders and has not undergone the wider reviews of a TIR or standard and offers an even greater response time.

CAUTION NOTICE: This AAMI CR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, technical information reports, consensus reports and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this document are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Rd, Suite 300, Arlington, VA 22203.
## Contents

<table>
<thead>
<tr>
<th>Task Group representation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgments</td>
<td>v</td>
</tr>
<tr>
<td>Purpose</td>
<td>1</td>
</tr>
<tr>
<td>1 Working Pressure</td>
<td>1</td>
</tr>
<tr>
<td>2 Accessories</td>
<td>1</td>
</tr>
<tr>
<td>3 Resistance to flow (pressure drop)</td>
<td>1</td>
</tr>
<tr>
<td>4 Breathing during single fault condition</td>
<td>2</td>
</tr>
<tr>
<td>5 CO₂ Rebreathing</td>
<td>2</td>
</tr>
<tr>
<td>6 Fresh Gas Port</td>
<td>2</td>
</tr>
<tr>
<td>7 Reuse hazards</td>
<td>2</td>
</tr>
<tr>
<td>8 Biocompatibility</td>
<td>2</td>
</tr>
<tr>
<td>9 Risk Management Process</td>
<td>3</td>
</tr>
<tr>
<td>10 Acoustic noise</td>
<td>3</td>
</tr>
<tr>
<td>11 Oxygen enriched environment</td>
<td>3</td>
</tr>
<tr>
<td>12 Volume</td>
<td>4</td>
</tr>
</tbody>
</table>
Task Group representation

Association for the Advancement of Medical Instrumentation

COVID-19 Response Team Members

This AAMI Consensus Report (CR) was developed by a task group under the auspices of the AAMI COVID-19 Response Team.

The **AAMI COVID-19 Response Team** had the following members:

**Cochairs:** Jennifer Danieley  
David Feinstein  
Julian Goldman  
Sandy Weininger

**Members:** Simona Bancos, FDA/CDRH  
Andrew Bath, ResMed Inc.  
Brandon Blakely, FDA/CDRH  
Brad Bonnette, ECRI Institute  
Caitlin Brady, Intertek  
David Busch, UT Southwestern Medical Center  
Anthony Ciccarello, Philips  
Steven Dain, University of Western Ontario  
Rakhi Dalal, FDA/CDRH  
Jennifer Danieley, FDA/CDRH  
Andy Doering, Medtronic  
Simon Dunham, Weill Cornell Medicine  
David Feinstein, American Society of Anesthesiologists (ASA)  
Bruce Friedman, GE Healthcare  
Hamed Ghods, FDA/CDRH  
Julian Goldman, Partners HealthCare System  
Ralf Heesch, Draeger Medical Systems Inc.  
Heidi Horn, Nuvolo Technologies  
Fernando Isaza, Philips  
Michael Jaffe, Cardiorespiratory Consulting LLC  
Gardner Kimm, Medtronic Inc Campus  
Robert Kopotic, Edwards Lifesciences  
Hubertus Lasthaus, VitalAire Germany  
Ed Madsen, Avanos Medical  
Phoebe Mainland, Alfred Health  
Madeleine Manousaridis, Standards Australia  
Benoit Marchal, Air Liquide  
Thomas Marmet, GE Healthcare  
Debra Milamed, Harvard University  
Cyndy Miller, Medtronic Inc Campus  
Bryant Moeller, ResMed Inc.  
Curtis Morgan, 3M Health Care  
Akito Ohmura, Teikyo University-Mizonokuchi Hospital  
David Osborn, Philips  
John Stark, 3M Health Care  
Robert Steurer, Steurer Consulting Group  
Dongbo Wang, FDA/CDRH  
Sandy Weininger, FDA/CDRH  
Ayub Yancheshmeh, CSA Group

NOTE—Participation by federal agency representatives in the development of this document does not constitute endorsement by the federal government or any of its agencies.
Acknowledgments

AAMI gratefully acknowledges the writing team members, Prepared by Brad Bonnette, Anthony Ciccarello, Rakhi Dalal, Julian Goldman, Barry Hunt, Bob Kopotic, Ken LeDez, Cyndy Miller, Dave Osborn and Sandy Weininger for their outstanding and expeditious work in preparing these drafts for committee review and approval.
End user disclosures for emergency use Ventilatory Assistance Helmet (VAH)

Purpose

This document identifies safety related disclosures to be provided to end users of Emergency Use VAH. These details are based on the hazards identified in IEC 60601-1 and ISO 17510.

1 Working Pressure

Purpose: to ensure compatibility of the VAH interface with the patient and source of ventilatory assist.

Disclosures:

Indicate the rated:

- MAXIMUM WORKING PRESSURE
- minimum pressure

2 Accessories

Purpose: to ensure the safe use of the VAH with compatible accessories.

Disclosures:

List of recommended accessories and their replacement intervals e.g., tubing, filters, valves, monitoring systems.

List of recommended fresh gas sources e.g. ventilators, ventilatory assist equipment, gas mixers, flow meters.

3 Resistance to flow (pressure drop)

Purpose: to ensure the patient receives the required therapeutic pressure and to limit the inspiratory and expiratory resistance to an acceptable level.

Disclosures:

Inspiratory resistance: The resistance to inspiratory flow derived from pressure drop between the patient connection port and the patient measured at 50L/min and 100L/min.

---

1 Medical electrical equipment – Part 1: General requirements for basic safety and essential performance
2 Medical devices — Sleep apnoea breathing therapy — Masks and application accessories
4 Expiratory resistance: The resistance to expiratory flow derived from pressure drop between the interior of the VAH and ambient, measured at 50L/min and 100L/min.

4 Breathing during single fault condition

Purpose: to limit breathing resistance and to prevent excessive rebreathing when there is insufficient fresh gas flow from the ventilatory assist equipment during a single fault condition.

Disclosures:

If an anti-asphyxia valve is provided, the open-to-atmosphere and closed-to-atmosphere pressures shall be disclosed.

If an anti-asphyxia valve is not provided in the VAH, manufacturers shall disclose the means by which the patient shall access fresh gas in the case of a SINGLE FAULT CONDITION.

Manufacturers shall disclose the necessity of continual monitoring of the patient by the operator and/or by monitoring equipment capable of creating alarm conditions in the case of faults.

5 CO2 Rebreathing

Purpose: to reduce the risk of excessive inspired carbon dioxide

Disclosures:

Disclose the minimum flow required to prevent unacceptable CO2 rebreathing.

Describe the means implemented to minimize the risk of rebreathing exhaled CO2. The means can be included in the VAH or the equipment providing gas delivery or ventilation.

6 Fresh Gas Port

Purpose: since the source of fresh gas is not included in the VAH, identify the pressure or supplemental oxygen delivery interface.

Disclosures:

Disclose the means of interfacing with the fresh gas delivery system or ventilatory assist device.

7 Reuse hazards

Purpose: to reduce the risk of cross-contamination.

Disclosures:

Describe the cleaning and disinfection procedures needed between uses and between patients for both the VAH and accessories.

Description of location and specifications of required VAH viral filters and replacement intervals.

8 Biocompatibility

Purpose: to reduce the risk of biological reaction to foreign substances.

Disclosures:
For the gas pathway, indicate if any biocompatibility evaluations were performed per ISO 18562 (series)\(^3\).

For parts intended to touch the patient, indicate if any biocompatibility evaluations were performed per ISO 10993 (series)\(^4\).

### 9 Risk Management Process

**Purpose:** to ensure risks were comprehensively identified and adequately managed.

**Disclosures:**

Indicate whether the VAH design has been developed using a risk management process (e.g., ISO 14971\(^5\)).

### 10 Acoustic noise

**Purpose:** to ensure acoustic noise inside the VAH is at an acceptable patient level.

**Disclosures:**

Disclose if hearing protection is necessary and provided by the VAH manufacturer. If not provided by the VAH manufacturer provide the requirements for such hearing protection.

If measured, disclose in dBA the acoustic noise level measured at the minimum required fresh gas flowrate.

### 11 Oxygen enriched environment

**Purpose:** to reduce the risk of thermal injury resulting from ignition of the VAH or its accessories when the VAH is used with supplemental oxygen therapy.

**Disclosures:**

Indicate that electronic devices used inside or in the vicinity of the VAH shall be suitable for use in an oxygen enriched environment > 25 % O\(_2\). Examples of electronic devices are microphones, headphones, cell phones, and electro-medical devices.

Indicate that the use of lotions, salves, dressing, makeup, or lubricants (e.g., grease for O-rings and fittings on device) in an oxygen enriched environment requires special consideration.

If alcohol or flammable cleaning or disinfection agents are used, ensure that they have completely evaporated prior to use.

**Examples:**

a warning statement to the effect that "WARNING: Use only water-based lotions, salves or dressings that are oxygen-compatible before and during oxygen therapy. Never use these products to avoid the risk of fire and burns".

---

\(^3\) Biocompatibility evaluation of breathing gas pathways in healthcare applications.

\(^4\) Biological evaluation of medical devices

\(^5\) Medical devices - Application of risk management to medical devices
a warning statement to the effect that “WARNING: Do not use lubricant for any fittings, connections, tubing, or other accessories unless certified for use in an oxygen enriched atmosphere to avoid the risk of fire and burns.”

12 Volume

Purpose: Provide health care providers with information to better understand the device.

Disclosures:

- Approximate volume of gas with the helmet during NORMAL USE